206 related articles for article (PubMed ID: 32470937)
1. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis type 2 versus sporadic vestibular schwannoma: The utility of MR diffusion and dynamic contrast-enhanced imaging.
Ota Y; Liao E; Capizzano AA; Baba A; Kurokawa R; Kurokawa M; Srinivasan A
J Neuroimaging; 2022 May; 32(3):554-560. PubMed ID: 35037337
[TBL] [Abstract][Full Text] [Related]
3. Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma.
Marioni G; Nicolè L; Cazzador D; Pavone C; D'Avella D; Martini A; Mazzoni A; Zanoletti E
Head Neck; 2019 Oct; 41(10):3612-3617. PubMed ID: 31313389
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma.
Lewis D; Roncaroli F; Agushi E; Mosses D; Williams R; Li KL; Zhu X; Hinz R; Atkinson R; Wadeson A; Hulme S; Mayers H; Stapleton E; Lloyd SKL; Freeman SR; Rutherford SA; Hammerbeck-Ward C; Evans DG; Pathmanaban O; Jackson A; King AT; Coope DJ
Neuro Oncol; 2019 Feb; 21(3):314-325. PubMed ID: 30388263
[TBL] [Abstract][Full Text] [Related]
5. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
6. Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
Li KL; Djoukhadar I; Zhu X; Zhao S; Lloyd S; McCabe M; McBain C; Evans DG; Jackson A
Neuro Oncol; 2016 Feb; 18(2):275-82. PubMed ID: 26311690
[TBL] [Abstract][Full Text] [Related]
7. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
Baser ME; Makariou EV; Parry DM
J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
[TBL] [Abstract][Full Text] [Related]
8. Facial Nerve Outcomes After Vestibular Schwannoma Microsurgical Resection in Neurofibromatosis Type 2.
Sobieski C; Killeen DE; Barnett SL; Mickey BE; Hunter JB; Isaacson B; Kutz JW
Otolaryngol Head Neck Surg; 2021 Apr; 164(4):850-858. PubMed ID: 32957864
[TBL] [Abstract][Full Text] [Related]
9. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.
Mautner VF; Baser ME; Thakkar SD; Feigen UM; Friedman JM; Kluwe L
J Neurosurg; 2002 Feb; 96(2):223-8. PubMed ID: 11838794
[TBL] [Abstract][Full Text] [Related]
10. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.
Picry A; Bonne NX; Ding J; Aboukais R; Lejeune JP; Baroncini M; Dubrulle F; Vincent C
Laryngoscope; 2016 Oct; 126(10):2358-62. PubMed ID: 27075822
[TBL] [Abstract][Full Text] [Related]
11. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.
Dewan R; Pemov A; Kim HJ; Morgan KL; Vasquez RA; Chittiboina P; Wang X; Chandrasekharappa SC; Ray-Chaudhury A; Butman JA; Stewart DR; Asthagiri AR
Neuro Oncol; 2015 Apr; 17(4):566-73. PubMed ID: 25452392
[TBL] [Abstract][Full Text] [Related]
12. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
[TBL] [Abstract][Full Text] [Related]
13. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
14. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas.
Hong B; Krusche CA; Schwabe K; Friedrich S; Klein R; Krauss JK; Nakamura M
Neurosurgery; 2011 Apr; 68(4):1112-7. PubMed ID: 21221032
[TBL] [Abstract][Full Text] [Related]
16. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
Tamura R; Morimoto Y; Sato M; Kuranari Y; Oishi Y; Kosugi K; Yoshida K; Toda M
J Neurooncol; 2020 Jan; 146(2):265-273. PubMed ID: 31897926
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2.
Li H; Hao SY; Wang L; Li D; Wu Z; Zhang LW; Zhang JT
Acta Neurochir (Wien); 2015 Nov; 157(11):1983-90. PubMed ID: 26287269
[TBL] [Abstract][Full Text] [Related]
18. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
19. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Imaging in the Diagnosis and Management of Patients With Vestibular Schwannomas.
Dunn IF; Bi WL; Mukundan S; Delman BN; Parish J; Atkins T; Asher AL; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E32-E34. PubMed ID: 29309686
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
